Obesity Treatment Options in 2026

Summary: Obesity treatment in 2026 follows a tiered hierarchy: lifestyle therapy as the foundation, GLP-1 medications for BMI 30 and above, bariatric surgery for BMI 40 and above or 35 with comorbidity, and older drugs for specific cases.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Obesity treatment in 2026 is a tiered system. Lifestyle therapy is the foundation. GLP-1 medications sit on top of that foundation for people with a BMI of 30 or higher, or 27 with a weight-related comorbidity. Bariatric surgery is the option for people with a BMI of 40 or higher, or 35 with comorbidity. Older medications and devices fill specific niches. Every serious clinical guideline, from the ASMBS to the AACE to the obesity standards published in the ADA journals, follows that hierarchy in some form.

The tiers are not a ladder you walk in order. They are categories of intensity, and the right starting tier depends on your BMI, your comorbidities, how much weight you need to lose, and how you have responded to previous attempts. A 38-year-old with a BMI of 45 and uncontrolled type 2 diabetes is not starting at "eat less and walk more." They are a candidate for surgery and a GLP-1, day one.

This page is the map. What each tier achieves on average, who it is for, what the evidence says, and how the tiers combine.

The 2026 treatment hierarchy at a glance

The percentages are total body weight reduction from baseline. They are averages across pivotal trials and large registry data. Individual results vary, and combinations of tiers (a GLP-1 plus intensive lifestyle therapy, or surgery plus a GLP-1 for inadequate response) routinely outperform single-tier averages.

Tier one: lifestyle therapy

Lifestyle therapy is not "diet and exercise." That phrase is the reason it gets dismissed. The clinical version is a structured program that combines a reduced-calorie eating plan, programmed physical activity, and behavioral counseling delivered by trained staff over months. The benchmark is the Diabetes Prevention Program protocol and its descendants, which produce 5 to 7 percent weight loss at one year when delivered with full fidelity.

The three components matter together. A calorie deficit alone produces weight loss but does not durably change eating behavior. Exercise alone is a weak weight-loss intervention but is the single strongest predictor of weight maintenance after loss. Behavioral counseling closes the gap between intention and execution, which is where most attempts fail.

What lifestyle therapy actually involves

• A daily energy deficit of 500 to 750 kilocalories, typically targeting 1,200 to 1,500 kcal per day for women and 1,500 to 1,800 kcal per day for men, adjusted for body size.
• 150 to 300 minutes per week of moderate-intensity aerobic activity, plus resistance training twice a week.
• Structured behavioral support: self-monitoring of food intake and weight, goal setting, stimulus control, problem-solving for relapses. Sixteen to twenty-six sessions in the first six months is the dose that the USPSTF and CMS reimbursement structures are built around.

Lifestyle therapy is the foundation for every other tier. Surgery patients who do not change their eating patterns regain weight. GLP-1 patients who stop the medication without behavior change regain weight. The drug and the operation make sustained behavior change physiologically easier, but neither replaces it.

Tier two: GLP-1 and dual-incretin medications

The second tier is the one that changed obesity treatment in the 2020s. Semaglutide (Wegovy) was the first GLP-1 receptor agonist to deliver double-digit weight loss in a generalizable trial population. Tirzepatide (Zepbound), a dual GIP and GLP-1 agonist, beat it. Liraglutide (Saxenda), an older daily GLP-1, was the first FDA-approved GLP-1 for obesity and still has a role, particularly in adolescents and in patients who tolerate it better than the weekly agents.

What the pivotal trials showed

The STEP 1 trial randomized 1,961 adults with a BMI of 30 or higher (or 27 with a weight-related comorbidity) to weekly semaglutide 2.4 mg or placebo, both with lifestyle intervention, for 68 weeks. Mean weight loss with semaglutide was 14.9 percent versus 2.4 percent with placebo. Over a third of the semaglutide group lost 20 percent or more of body weight ^[2].

SURMOUNT-1 randomized 2,539 adults to weekly tirzepatide at 5, 10, or 15 mg, or placebo, for 72 weeks. The 15 mg dose produced a mean weight reduction of 20.9 percent. The 10 mg dose produced 19.5 percent. Placebo produced 3.1 percent. Roughly 57 percent of patients on 15 mg lost 20 percent or more of body weight, and 36 percent lost 25 percent or more ^[3].

These numbers are not subtle. They are roughly four to seven times what lifestyle therapy alone produces, and they approach the lower end of what bariatric surgery achieves.

Who is eligible

The FDA labels for Wegovy and Zepbound match the standard obesity drug indication: BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbid condition such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease ^[4]. The same threshold applies to the older agents (Contrave, Saxenda, Qsymia).

In 2024 the FDA expanded the Wegovy label to include cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, regardless of diabetes status. Zepbound holds approvals for obesity and moderate-to-severe obstructive sleep apnea in adults with obesity. The indications are widening, not narrowing.

Side effects, cost, and the long-term question

GLP-1 side effects are dominated by gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation. They are dose dependent. The titration schedules built into both Wegovy and Zepbound exist to let the gut adapt, and people who follow the schedule rather than chase the maximum dose tend to tolerate the drug well. Less common but more serious risks include pancreatitis, gallbladder disease at the rates seen with rapid weight loss, and a theoretical thyroid C-cell tumor signal carried over from rodent studies that has not appeared in human trial data.

Cost is the real-world barrier. List prices in the US are around $1,000 to $1,300 per month for both brand drugs. Coverage is patchy. Most commercial plans cover GLP-1s for type 2 diabetes universally. Coverage for obesity without diabetes varies plan by plan, and Medicare did not cover obesity drugs at all under federal law until partial expansions tied to cardiovascular indications began in 2024 and 2025.

Compounded GLP-1s filled the gap during the 2022 to 2024 shortage and remain a cash-pay option, but the FDA removed semaglutide and tirzepatide from the shortage list in 2024 and 2025 respectively, and the legal status of compounded versions is now narrower. State-by-state telehealth differences make this messy. An obesity medicine specialist can usually navigate the coverage maze faster than a primary care practice that handles five obesity patients a month.

The maintenance problem

When people stop taking a GLP-1, weight returns. The STEP 4 extension trial showed that patients randomized to placebo after a year on semaglutide regained two thirds of their lost weight by the end of the follow-up period. This is not a failure of the drug. It is the physiology of obesity reasserting itself once the medication that suppresses it is removed. Plan for indefinite use, or plan for some regain.

Tier three: older anti-obesity medications

Before the GLP-1 era, FDA-approved obesity drugs produced 3 to 9 percent weight loss at one year. They are still on the market and still useful, particularly when GLP-1s are not tolerated, not covered, or not preferred.

Phentermine is the most prescribed obesity drug in the US by volume, and it costs pennies. Contrave is an option for people whose obesity has a strong food-reward or emotional-eating pattern, since bupropion blunts reward circuitry ^[5]. Orlistat is the only one available over the counter (as alli at half strength), and is mostly relevant for patients who cannot use any centrally acting drug.

Setmelanotide deserves a specific note. It is approved for a narrow set of genetic obesity disorders: pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome. For those patients the drug is transformative. For everyone else it is not the answer.

Tier four: bariatric and metabolic surgery

Bariatric surgery is the most effective obesity treatment that exists. Mean total body weight loss is 25 to 35 percent at one to two years and remains in the 20 to 30 percent range at ten years for the most-studied procedures. Type 2 diabetes remission rates are 30 to 60 percent within one year for patients with diabetes at baseline. The 2022 ASMBS and IFSO joint position lowered the BMI threshold and broadened the indication ^[1].

Current ASMBS indications (2022 update)

• BMI of 35 or higher, regardless of comorbidities.
• BMI of 30 to 34.9 with metabolic disease, particularly type 2 diabetes that is not adequately controlled by medical and lifestyle therapy.
• Adolescents with a BMI of 120 percent of the 95th percentile and a major comorbidity, or a BMI of 140 percent of the 95th percentile regardless of comorbidity.

The earlier threshold of BMI 40 (or 35 with comorbidity) that was set by the 1991 NIH consensus statement is obsolete. The 2022 ASMBS guidance reflects three decades of additional outcomes data showing that the procedures are safer and more effective than the original guidelines assumed.

The four main procedures

The lap band is still classified as bariatric surgery, but it is rarely chosen in 2026. It produces the least weight loss of the four procedures and has the highest reoperation rate for band slippage, erosion, or inadequate response. Most US bariatric programs offer it only for patients who specifically request it after counseling on alternatives. The sleeve and the bypass account for over 90 percent of US procedures.

The sleeve is now the most common operation in the US. It is technically simpler than bypass, avoids the malabsorption that bypass causes, and produces nearly equivalent weight loss at one to two years. The bypass remains the better choice for patients with severe gastroesophageal reflux disease (the sleeve can worsen reflux), and for patients with type 2 diabetes who would benefit from the stronger metabolic effect of intestinal rerouting.

Insurance coverage

Medicare covers sleeve gastrectomy, gastric bypass, biliopancreatic diversion with duodenal switch, and adjustable gastric banding for patients who meet the BMI and comorbidity criteria and complete a documented medical weight-loss program. Most commercial insurers, including Cigna and Aetna, follow the same general framework but layer on plan-specific requirements: six-month supervised diet documentation, psychological evaluation, nutritional counseling, and tobacco cessation. The bar is real but predictable.

The biggest insurance pitfall is the "obesity treatment exclusion" rider that some employer-sponsored plans carry. If your plan documents say obesity treatment is not covered, surgery is not covered, period. Check the plan summary before you start a six-month program.

Combining surgery with GLP-1s

A growing share of bariatric programs prescribe GLP-1 medications after surgery for patients whose weight loss is plateauing below the expected range, or whose weight has started to regain. The combination of surgical anatomy plus pharmacologic appetite suppression produces additional 5 to 10 percent total body weight loss in registry data. It is not a rescue strategy reserved for failures. It is becoming the standard of care for inadequate response.

How the tiers combine in practice

The clinical reality is not "pick one tier." A typical 2026 obesity treatment plan layers them:

• A 36-year-old with a BMI of 32 and prediabetes starts intensive lifestyle therapy plus weekly semaglutide. The lifestyle program is the maintenance scaffolding, the drug is the appetite override.
• A 48-year-old with a BMI of 47, type 2 diabetes, and obstructive sleep apnea is referred for sleeve gastrectomy after the standard medical clearances. She begins lifestyle counseling during the six-month preoperative window. Postoperatively she stays on metformin and tapers off her sulfonylurea as her glucose normalizes. If her weight loss plateaus below 20 percent at one year, her surgeon adds tirzepatide.
• A 58-year-old with a BMI of 31, well-controlled hypertension, and a history of cholelithiasis cannot tolerate GLP-1 nausea. She does well on phentermine-topiramate ER plus structured lifestyle support, losing 9 percent of body weight at one year.

There is no single right plan. There is the plan that matches your BMI, your comorbidities, your tolerance, your coverage, and what you will actually adhere to for the rest of your life.

What obesity is, what overweight is, what morbid obesity is

BMI categories define the language of obesity treatment. They are imperfect (a muscular athlete and a sedentary office worker with the same BMI have very different metabolic risk), but they remain the practical threshold tool used by every insurer and every clinical guideline.

The CDC's 2026 surveillance data places adult obesity prevalence in the United States at roughly 42 percent, with severe (class III) obesity at around 10 percent. Prevalence is highest in non-Hispanic Black adults and lowest in non-Hispanic Asian adults, with persistent disparities in access to specialist care, surgical referral rates, and GLP-1 coverage. The disparity in treatment access has narrowed in some states with Medicaid expansion of GLP-1 coverage, but remains substantial.

The term "morbid obesity" is the older clinical label for class III obesity. Both terms are correct. Many specialists prefer "severe obesity" in patient-facing contexts because it carries less stigma.

Treating obesity-related complications

Obesity drives a long list of comorbid conditions, and treating the obesity often improves them more than treating the complication directly. A short tour of the most common.

Cardiometabolic complications

Type 2 diabetes: GLP-1 agents lower HbA1c by 1.5 to 2.0 percentage points and produce meaningful weight loss. Bariatric surgery induces remission in 30 to 60 percent of patients within one year. The decreased HbA1c following bariatric surgery is among the strongest metabolic effects medicine has documented.

Hypertension and dyslipidemia: Most respond to weight loss of 10 percent or more, with reductions in blood pressure and improvements in lipid panels that often allow dose reduction or discontinuation of cardiometabolic medications.

Organ-specific complications

Obesity-related glomerulopathy is a kidney disease driven by hyperfiltration from excess adiposity. Treatment combines weight loss (GLP-1s have proteinuria-reducing effects independent of weight) with standard renal protective agents (ACE inhibitors or ARBs, SGLT2 inhibitors). For severe disease, bariatric surgery produces sustained improvement in proteinuria and stabilization of GFR.

Metabolic-dysfunction-associated steatotic liver disease (formerly NAFLD/NASH) is the hepatic manifestation of obesity. The 2024 FDA approval of resmetirom (Rezdiffra) for MASH with moderate to advanced fibrosis added a targeted drug to a treatment toolkit that previously rested entirely on weight loss. GLP-1s and tirzepatide produce significant improvement in liver fat and inflammation in trial data. For end-stage cirrhosis from obesity, transplantation is the answer, and obesity treatment becomes the post-transplant maintenance strategy.

Obesity hypoventilation and obstructive sleep apnea: Weight loss of 10 percent or more reduces apnea-hypopnea index in most patients. CPAP is the immediate symptomatic treatment. The FDA approval of tirzepatide for moderate to severe OSA in adults with obesity is a recent addition that makes the same drug useful for both the disease and one of its largest complications.

Obesity-related leg pain, lymphedema, and venous insufficiency: Weight loss reduces axial loading on knees and hips, improves lymphatic flow, and reduces venous pressure. Compression therapy, physical therapy, and bariatric or pharmacologic weight management are the combined approach. Surgical lymphatic procedures (lymphovenous anastomosis, vascularized lymph node transfer) are second-line for refractory disease.

Special populations and edge cases

Hypothalamic obesity

Hypothalamic obesity follows damage to appetite-regulating circuits in the hypothalamus, most commonly from craniopharyngioma surgery, traumatic brain injury, or radiation. The standard anti-obesity drugs are usually inadequate. Setmelanotide and the GLP-1 agents have produced encouraging results in small studies. Tertiary obesity centers with specific hypothalamic obesity programs are where these patients belong.

Genetic obesity

Single-gene obesity (POMC deficiency, LEPR deficiency, MC4R variants, Bardet-Biedl syndrome) accounts for a small fraction of severe early-onset obesity but is the population most likely to benefit from precision pharmacology. Setmelanotide is approved for several of these syndromes ^[1]. Genetic testing is appropriate when severe obesity began before age five, when family history is striking, or when a syndromic phenotype is present.

Metabolically healthy obesity

A subset of people with obesity have normal blood pressure, normal lipids, normal glucose, and normal liver function. This phenotype is real and measurable. It is not, however, stable. Most "metabolically healthy" individuals progress to metabolic dysfunction within five to ten years. Treatment intensity is calibrated to risk, but the absence of current metabolic disease is not a reason to defer all treatment in a patient who wants to address weight.

Gynoid and pear-shaped obesity

Fat distribution matters as much as total fat mass. Android (apple-shaped) obesity, with predominant visceral fat, carries higher metabolic risk than gynoid (pear-shaped) obesity, with predominant gluteofemoral fat. Both respond to the same treatment hierarchy, but the urgency and the expected metabolic benefit per pound lost differ. Imaging (DEXA, waist circumference, waist-to-hip ratio) refines risk stratification beyond BMI.

Where care happens: obesity specialists, primary care, and telehealth

The American Board of Obesity Medicine certifies physicians who complete additional training in obesity treatment. As of 2026 there are over 8,000 ABOM-certified physicians in the US. They sit in academic obesity centers, in private specialty clinics, and increasingly in telehealth practices.

Primary care can manage the majority of obesity treatment, particularly the lifestyle tier and uncomplicated GLP-1 initiation. The specialist comes in for patients with multiple failed treatment attempts, complex comorbidities, severe (class III) obesity, suspected genetic syndromes, or post-surgical inadequate response.

Telehealth obesity care expanded rapidly during the GLP-1 shortage and remains substantial in 2026. The quality range is wide. The good services pair a licensed clinician with structured lifestyle support and use compounded medications only when clinically justified. The bad services are pill mills that ship the drug without meaningful evaluation. State medical board enforcement is uneven, and the patient's job is to ask the same questions of a telehealth provider that they would ask of an in-person clinic.

The best obesity treatment hospitals in the US (the high-volume bariatric centers of excellence accredited by the MBSAQIP) publish their outcome data. Surgery at a high-volume center produces measurably better outcomes than surgery at a low-volume center. For UK readers, NHS Tier 3 and Tier 4 obesity services follow a similar pathway: a Tier 3 multidisciplinary medical weight-management program, with referral to Tier 4 bariatric surgery for patients who meet thresholds.

The ethics of obesity treatment

The bioethics literature on obesity treatment is active in 2026. Three live debates.

Drug access. The most effective obesity drugs cost more per year than most patients can pay out of pocket, and insurance coverage is patchy. The result is that the most effective treatment for a disease that disproportionately affects lower-income populations is least available to them.

Adolescent treatment. AAP guidelines now endorse obesity drugs from age 12 and bariatric surgery in selected adolescents. Critics worry about long-term safety. Proponents point to the strong predictive value of adolescent obesity for adult comorbidity and mortality and argue that withholding effective treatment is itself a harm.

Weight bias in clinical decision-making. Patients with obesity describe consistent experiences of being attributed every symptom to weight and being denied other diagnostic workups. Treatment access disparities by race, geography, and insurance type compound the problem. The professional response, codified in updated AACE and Obesity Society position statements, is to treat obesity as a disease and weight bias as a quality-of-care defect.

Frequently asked questions about obesity treatment

What is the most effective obesity treatment in 2026?

Bariatric surgery produces the largest and most durable weight loss (25 to 35 percent of body weight on average). Tirzepatide is the most effective non-surgical option, with mean 20 percent weight loss in SURMOUNT-1.

What is bariatric surgery?

Bariatric surgery is a group of procedures that modify the stomach (and sometimes the small intestine) to reduce caloric intake and alter appetite hormones. The most common procedures are sleeve gastrectomy and Roux-en-Y gastric bypass.

Is lap band considered bariatric surgery?

Yes. The adjustable gastric band (lap band) is one of four FDA-approved bariatric procedures, although it has fallen out of favor because it produces less weight loss and a higher reoperation rate than sleeve or bypass.

Does Medicare cover bariatric surgery?

Medicare covers sleeve gastrectomy, gastric bypass, duodenal switch, and adjustable gastric banding for patients with a BMI of 35 or higher and at least one comorbidity, who have completed a documented medical weight-loss program at a facility certified by the MBSAQIP.

Does Cigna cover bariatric surgery?

Most Cigna commercial plans cover bariatric surgery for patients meeting BMI and comorbidity thresholds, with documentation of a supervised weight-loss program (typically six months), psychological evaluation, and nutritional counseling. Coverage depends on the specific plan and any obesity-exclusion riders.

What is morbid obesity?

Morbid obesity is the older clinical term for class III obesity, defined as BMI of 40 or higher. Many specialists now use "severe obesity" instead. Both terms refer to the same diagnostic threshold.

What is the difference between overweight and obesity?

Overweight is a BMI of 25.0 to 29.9. Obesity is a BMI of 30 or higher. The cutoffs are based on epidemiologic data linking BMI to cardiovascular and metabolic risk.

How much weight do you lose on GLP-1 drugs?

Average total body weight loss is around 15 percent on semaglutide 2.4 mg weekly (STEP 1) and around 20 percent on tirzepatide 15 mg weekly (SURMOUNT-1). Individual results vary widely. Roughly a third of patients lose 20 percent or more on the maximum doses.

Can you treat obesity with lifestyle changes alone?

Yes, but the average weight loss is modest (3 to 8 percent) and durability is poor without ongoing support. Lifestyle therapy is the foundation of every treatment plan and is the only tier that does not require medication or surgery.

Does losing weight reverse type 2 diabetes?

Substantial weight loss often induces type 2 diabetes remission. Bariatric surgery produces remission in 30 to 60 percent of patients within one year. GLP-1 medications produce remission in a smaller but meaningful share. Remission is most likely in patients diagnosed within the past five years.

Is obesity treatment covered by insurance?

Coverage varies. Bariatric surgery is widely covered for patients meeting criteria. GLP-1 coverage for obesity (rather than diabetes) is more variable and depends on the specific plan. Lifestyle therapy is covered by Medicare and most commercial plans when delivered by an eligible provider.

What is metabolically healthy obesity?

Metabolically healthy obesity describes people with a BMI in the obesity range but normal blood pressure, lipids, glucose, and liver function. Most progress to metabolic disease within a decade, so the absence of current metabolic dysfunction is not a reason to defer treatment indefinitely.

When is bariatric surgery recommended over medication?

Bariatric surgery is recommended for BMI of 40 or higher regardless of comorbidities, BMI of 35 or higher with one or more comorbidities, or BMI of 30 or higher with poorly controlled type 2 diabetes. It is also considered for patients who have not reached treatment goals on medications alone.

How long do you stay on obesity medications?

Obesity is a chronic disease and obesity medications are intended for long-term use. Most patients who stop a GLP-1 regain a significant share of lost weight within a year. Plan for ongoing therapy unless your clinician advises otherwise.

The plan that works is the plan you stay on

There is no shortcut around the central rule of obesity treatment in 2026. The best plan is the one matched to your BMI, your comorbidities, and your tolerance, delivered by clinicians who treat obesity as the chronic disease it is, and continued for as long as your body needs it. The treatment hierarchy is a menu, not a sequence. Start where the evidence says you should start. Layer the tiers when the evidence supports it. Stay in care.